17588471420251

Ocrevus^®IV (ocrelizumab) 300mg vial, and Ocrevus^® SC (ocrelizumab 920 mg/23 mL solution for subcutaneous injection) are Prescription Medicines used to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Ask your doctor if Ocrevus is right for you.

Ocrevus IV when given as an infusion into the vein and Ocrevus SC when given as an injection under the skin, are funded medicines for patients who meet defined criteria.
Ask your health professional about the cost of the medicine and other fees that may apply.

Use only as directed. If symptoms continue or you have side effects, see your healthcare professional.
For more information about Ocrevus:

• talk to your health professional; or
• visit medsafe.govt.nz for Ocrevus Consumer Medicine Information; or
• visit getonwithlife.co.nz or call Roche on 0800 276 243.

Ocrevus has risks and benefits.

Possible common side effects include: Infusion-related reactions and injections reactions: symptoms can include itchiness, rash, hives or redness of the skin; throat irritation or pain; shortness of breath; swelling of the throat, face, lips, tongue, or other parts of the body; reactions in the area where the injection is given (Ocrevus SC only); redness on your face (flushing); low blood pressure; fever; fatigue; nausea; headache; fast heart beat Infections: viral infections (influenza); respiratory tract infections (runny nose, sneezing, sore throat, cough, fever, fatigue, weakness, shortness of breath); inflammation or infection of the sinuses – sinusitis (feeling of pressure or pain in the cheeks and forehead); inflammation or infection of the lung – bronchitis (cough, chest pain, fever); build-up of mucus in the nose and throat; infection of the stomach and bowel – gastroenteritis (nausea, vomiting, fever); eye inflammation or infection – conjunctivitis (itchy, red or sore eyes); or skin infection – cellulitis (rash, itching or hives on the skin).

Do not use Ocrevus if: you have had an allergic reaction to Ocrevus or any of the ingredients.

Tell your doctor if: you have any signs and symptoms of infection, or a history of a recurring or long-term infection such as hepatitis B; you are taking or have taken medicines which affect your immune system; you or your child intend to have or have had immunisation with any vaccine; you are allergic to any other medicines or any other substances such as foods, preservatives or dyes; have any other medical conditions; you take any medicines for any other condition (including those for MS, or to treat other conditions and medicines that lower blood pressure); you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop; you have any new medical conditions or plan to take any new medicines for any other condition; you have signs and symptoms that may indicate a liver problem Pregnancy: tell your doctor if you are pregnant or plan to become pregnant. You should avoid using Ocrevus during the second and third trimester of pregnancy, unless advised otherwise by your doctor. Breastfeeding: Talk to your doctor if you are breastfeeding or plan to breastfeed. You should avoid breastfeeding for the first few days after birth while you are using Ocrevus.

Tell your doctor immediately or go to your nearest Accident and Emergency Centre if you notice any of the following: Infusion-related reactions, injections reactions, or allergic reactions: symptoms can include itchy skin, rash, hives or redness of the skin; throat irritation or pain; shortness of breath; swelling of the throat, face, lips, tongue, or other parts of the body; reactions in the area where the injection is given (Ocrevus SC only); redness on your face (flushing); low blood pressure; fever; fatigue; nausea; headache; fast heart beat Infections: symptoms such as fever or chills; cough that does not go away; herpes (such as cold sore, shingles and genital sores) Progressive multifocal leukoencephalopathy (PML): think your multiple sclerosis is getting worse or if you or your partner or caregiver notice any new or unusual symptoms such as changes in movement or behaviour. There have been very rare reports of serious brain infection, called PML in patients receiving medicines for MS, which can cause severe disability or be life-threatening. Symptoms of PML can be similar to those of MS. Liver problems: symptoms such as new or worsening fatigue; loss of appetite; nausea; vomiting; pain in the right part of your abdomen; dark-coloured urine; yellowing of your skin or eyes.

Panel dated January 2026. All trademarks mentioned herein are protected by law. Roche Products (New Zealand) Limited, Auckland.

Privacy Statement | Legal Statement

© 2026, Roche Products (New Zealand) Ltd, Auckland. For more information about Roche, please visit www.roche.co.nz. This site contains information on Ocrevus which is intended for New Zealand consumers. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site. Models have been used throughout this website for illustrative purposes only.
M-NZ-00001395 v3/MR13038/MAR2026 This site was last updated March 2026.

You are about to leave the site to one that is not controlled or developed by Roche Products (New Zealand) Ltd.

Roche does not endorse or control, the content of any linked websites and if you click on any of those links you agree that Roche has no responsibility or duty to you for anything that happens to you as a result. If the linked site is outside New Zealand’s jurisdiction, the information may not be consistent with New Zealand’s legislation, advertising codes or the relevant New Zealand registered Data Sheet.

Please refer to the Data Sheet or Consumer Medicine Information on the Medsafe website for product information applicable to New Zealand.

Ok Continue Close